Quantification of Serum High Mobility Group Box 1 by Liquid Chromatography/High-Resolution Mass Spectrometry: Implications for Its Role in Immunity, Inflammation, and Cancer
High mobility group box 1 (HMGB1) is a non-histone chromosomal protein, which can be secreted through a variety of pathways and bind to pattern recognition receptors to release pro-inflammatory cytokines. Previous studies have suggested that HMGB1 is upregulated in numerous inflammatory diseases and...
Uloženo v:
| Vydáno v: | Analytical chemistry (Washington) Ročník 90; číslo 12; s. 7552 |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
19.06.2018
|
| ISSN: | 1520-6882, 1520-6882 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | High mobility group box 1 (HMGB1) is a non-histone chromosomal protein, which can be secreted through a variety of pathways and bind to pattern recognition receptors to release pro-inflammatory cytokines. Previous studies have suggested that HMGB1 is upregulated in numerous inflammatory diseases and that it could be a biomarker for such diseases. However, these studies used immunoassay-based methods to analyze serum HMGB1. Autoantibodies to HMGB1 in serum are found in healthy control subjects as well as in patients with different diseases. HMGB1 also binds to haptoglobin, a highly abundant plasma protein. This means that antibodies used in immunoassays must compete with binding of HMGB1 to endogenous serum HMGB1 autoantibodies and haptoglobin. To overcome these potential problems, we developed and validated a specific and sensitive assay based on stable isotope dilution and immunopurification to quantify HMGB1 in plasma and serum using two-dimensional nano-ultra-high-performance liquid chromatography parallel reaction monitoring/high-resolution mass spectrometry. Using this assay, we found that serum HMGB1 in 24 healthy control subjects (6.0 ± 2.1 ng/mL) was above the mean concentration reported for 18 different diseases (5.4 ± 2.8 ng/mL) where the analyses were conducted with immunoassay methodology. In light of our finding, the role of HMGB1 in these diseases will have to be re-evaluated. The concentration of HMGB1 in citrated and EDTA-treated plasma from the same healthy control subjects was below the limit of detection of our assay (1 ng/mL), confirming that HMGB1 in serum arises when blood is allowed to clot. This means that future studies on the role of HMGB1 in vivo should be conducted on plasma rather than serum. |
|---|---|
| AbstractList | High mobility group box 1 (HMGB1) is a non-histone chromosomal protein, which can be secreted through a variety of pathways and bind to pattern recognition receptors to release pro-inflammatory cytokines. Previous studies have suggested that HMGB1 is upregulated in numerous inflammatory diseases and that it could be a biomarker for such diseases. However, these studies used immunoassay-based methods to analyze serum HMGB1. Autoantibodies to HMGB1 in serum are found in healthy control subjects as well as in patients with different diseases. HMGB1 also binds to haptoglobin, a highly abundant plasma protein. This means that antibodies used in immunoassays must compete with binding of HMGB1 to endogenous serum HMGB1 autoantibodies and haptoglobin. To overcome these potential problems, we developed and validated a specific and sensitive assay based on stable isotope dilution and immunopurification to quantify HMGB1 in plasma and serum using two-dimensional nano-ultra-high-performance liquid chromatography parallel reaction monitoring/high-resolution mass spectrometry. Using this assay, we found that serum HMGB1 in 24 healthy control subjects (6.0 ± 2.1 ng/mL) was above the mean concentration reported for 18 different diseases (5.4 ± 2.8 ng/mL) where the analyses were conducted with immunoassay methodology. In light of our finding, the role of HMGB1 in these diseases will have to be re-evaluated. The concentration of HMGB1 in citrated and EDTA-treated plasma from the same healthy control subjects was below the limit of detection of our assay (1 ng/mL), confirming that HMGB1 in serum arises when blood is allowed to clot. This means that future studies on the role of HMGB1 in vivo should be conducted on plasma rather than serum.High mobility group box 1 (HMGB1) is a non-histone chromosomal protein, which can be secreted through a variety of pathways and bind to pattern recognition receptors to release pro-inflammatory cytokines. Previous studies have suggested that HMGB1 is upregulated in numerous inflammatory diseases and that it could be a biomarker for such diseases. However, these studies used immunoassay-based methods to analyze serum HMGB1. Autoantibodies to HMGB1 in serum are found in healthy control subjects as well as in patients with different diseases. HMGB1 also binds to haptoglobin, a highly abundant plasma protein. This means that antibodies used in immunoassays must compete with binding of HMGB1 to endogenous serum HMGB1 autoantibodies and haptoglobin. To overcome these potential problems, we developed and validated a specific and sensitive assay based on stable isotope dilution and immunopurification to quantify HMGB1 in plasma and serum using two-dimensional nano-ultra-high-performance liquid chromatography parallel reaction monitoring/high-resolution mass spectrometry. Using this assay, we found that serum HMGB1 in 24 healthy control subjects (6.0 ± 2.1 ng/mL) was above the mean concentration reported for 18 different diseases (5.4 ± 2.8 ng/mL) where the analyses were conducted with immunoassay methodology. In light of our finding, the role of HMGB1 in these diseases will have to be re-evaluated. The concentration of HMGB1 in citrated and EDTA-treated plasma from the same healthy control subjects was below the limit of detection of our assay (1 ng/mL), confirming that HMGB1 in serum arises when blood is allowed to clot. This means that future studies on the role of HMGB1 in vivo should be conducted on plasma rather than serum. High mobility group box 1 (HMGB1) is a non-histone chromosomal protein, which can be secreted through a variety of pathways and bind to pattern recognition receptors to release pro-inflammatory cytokines. Previous studies have suggested that HMGB1 is upregulated in numerous inflammatory diseases and that it could be a biomarker for such diseases. However, these studies used immunoassay-based methods to analyze serum HMGB1. Autoantibodies to HMGB1 in serum are found in healthy control subjects as well as in patients with different diseases. HMGB1 also binds to haptoglobin, a highly abundant plasma protein. This means that antibodies used in immunoassays must compete with binding of HMGB1 to endogenous serum HMGB1 autoantibodies and haptoglobin. To overcome these potential problems, we developed and validated a specific and sensitive assay based on stable isotope dilution and immunopurification to quantify HMGB1 in plasma and serum using two-dimensional nano-ultra-high-performance liquid chromatography parallel reaction monitoring/high-resolution mass spectrometry. Using this assay, we found that serum HMGB1 in 24 healthy control subjects (6.0 ± 2.1 ng/mL) was above the mean concentration reported for 18 different diseases (5.4 ± 2.8 ng/mL) where the analyses were conducted with immunoassay methodology. In light of our finding, the role of HMGB1 in these diseases will have to be re-evaluated. The concentration of HMGB1 in citrated and EDTA-treated plasma from the same healthy control subjects was below the limit of detection of our assay (1 ng/mL), confirming that HMGB1 in serum arises when blood is allowed to clot. This means that future studies on the role of HMGB1 in vivo should be conducted on plasma rather than serum. |
| Author | Blair, Ian A Mesaros, Clementina Weng, Liwei Guo, Lili Vachani, Anil |
| Author_xml | – sequence: 1 givenname: Liwei surname: Weng fullname: Weng, Liwei – sequence: 2 givenname: Lili surname: Guo fullname: Guo, Lili – sequence: 3 givenname: Anil surname: Vachani fullname: Vachani, Anil – sequence: 4 givenname: Clementina surname: Mesaros fullname: Mesaros, Clementina – sequence: 5 givenname: Ian A orcidid: 0000-0003-0366-8658 surname: Blair fullname: Blair, Ian A |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29791130$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkNtq3DAQhkVJaQ7tG5Qyl72INzrYlt27ZmmThQ0hSXu9jGU5q2JJjg5QP1TeMW66hV7NwP_N_8GckiPnnSbkI6MrRjm7QBVX6HBUe21XTUcZk9UbcsIqTou6afjRf_sxOY3xF10Yyup35Ji3smVM0BPyfJfRJTMYhcl4B36ABx2yhWvzuIcb35nRpBmugs8TXPrfwKCbYWuesulhvQ_eYvKPAaf9fPHnpLjX0Y_5tesGY4SHSau0YDqF-Qts7DQeVBEGH2CTItz7UYNxS2izW2znsHHDiNa-cueAblGhUzq8J28HHKP-cJhn5Of3bz_W18X29mqz_rotsGI0FVUrukahlgMfsGpqWWpFB6G4qlWphRK8b0TZy7pRS9DLEnVVC9k3fddiKzt-Rj7_7Z2Cf8o6pp01UelxRKd9jjtOSyEpr6lY0E8HNHdW97spGIth3v17MX8B3sWF1w |
| CitedBy_id | crossref_primary_10_3390_biom12040544 crossref_primary_10_1016_j_schres_2019_07_025 crossref_primary_10_1016_j_optlastec_2025_112953 crossref_primary_10_3390_biom13091335 crossref_primary_10_1021_acs_analchem_4c07095 crossref_primary_10_1002_pmic_202200059 crossref_primary_10_1074_jbc_REV120_012411 crossref_primary_10_1093_clinchem_hvz022 crossref_primary_10_3390_ph14060537 crossref_primary_10_1002_jssc_201900772 crossref_primary_10_1038_s42003_024_06930_y crossref_primary_10_1016_j_jprot_2025_105396 crossref_primary_10_1038_s42003_023_05472_z crossref_primary_10_1080_14789450_2025_2467263 |
| ContentType | Journal Article |
| DBID | NPM 7X8 |
| DOI | 10.1021/acs.analchem.8b01175 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Engineering Chemistry |
| EISSN | 1520-6882 |
| ExternalDocumentID | 29791130 |
| Genre | Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIEHS NIH HHS grantid: P30 ES013508 – fundername: NIEHS NIH HHS grantid: P42 ES023720 – fundername: NIEHS NIH HHS grantid: T32 ES019851 |
| GroupedDBID | --- -DZ -~X .DC .K2 23M 4.4 53G 55A 5GY 5RE 5VS 6J9 7~N 85S AABXI AAHBH ABHFT ABHMW ABJNI ABMVS ABOCM ABPPZ ABQRX ABUCX ACBEA ACGFO ACGFS ACGOD ACIWK ACJ ACKOT ACNCT ACPRK ACS ADHLV AEESW AENEX AFEFF AFRAH AGXLV AHGAQ ALMA_UNASSIGNED_HOLDINGS AQSVZ BAANH BKOMP CS3 CUPRZ D0L EBS ED~ EJD F5P GGK GNL IH9 IHE JG~ KZ1 LMP NPM P2P PQQKQ ROL RXW TAE TN5 UHB UI2 UKR VF5 VG9 W1F WH7 X6Y XSW YZZ ZCA ~02 7X8 ABBLG ABLBI |
| ID | FETCH-LOGICAL-a510t-593b8cae7f2fa58674ec0f3c2c6c4e3c32d834d768cec0d74ae5637d8db9a97b2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 21 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000436028800064&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1520-6882 |
| IngestDate | Thu Oct 02 04:17:40 EDT 2025 Thu Apr 03 06:53:30 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a510t-593b8cae7f2fa58674ec0f3c2c6c4e3c32d834d768cec0d74ae5637d8db9a97b2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0003-0366-8658 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC6417096 |
| PMID | 29791130 |
| PQID | 2043702603 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2043702603 pubmed_primary_29791130 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-06-19 |
| PublicationDateYYYYMMDD | 2018-06-19 |
| PublicationDate_xml | – month: 06 year: 2018 text: 2018-06-19 day: 19 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Analytical chemistry (Washington) |
| PublicationTitleAlternate | Anal Chem |
| PublicationYear | 2018 |
| SSID | ssj0011016 |
| Score | 2.38625 |
| Snippet | High mobility group box 1 (HMGB1) is a non-histone chromosomal protein, which can be secreted through a variety of pathways and bind to pattern recognition... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 7552 |
| Title | Quantification of Serum High Mobility Group Box 1 by Liquid Chromatography/High-Resolution Mass Spectrometry: Implications for Its Role in Immunity, Inflammation, and Cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29791130 https://www.proquest.com/docview/2043702603 |
| Volume | 90 |
| WOSCitedRecordID | wos000436028800064&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fSxwxEA6tFto-2NZaa61lCj663l2S22T7IlYqHvQOWxTu7cjmBxzorne7J94f5f_oTHYPfREKfdmXELJkJjNfMjPfMLbvrOFSk_VzxiTSpS4xXLskoPPXmZaOOxmbTajRSI_H2Xn74Fa1aZUrmxgNtSstvZF3qIZTEQGWOLqZJdQ1iqKrbQuNl2xdIJShg6nGj1EEuplGvlS6IiGUXJXO8V7H2OrQoKhwZ64PdR4ZK58HmdHZnL773998zzZamAnHjV58YC98sclen6y6u22yt0-ICD-y-z8L02QNRUFBGQCNyOIaKA0EhmXMoF1CfKiCn-Ud9CBfwu_pbDF1QPy6iHtb7usOTUkoKtDoNAwRngO1ua-JGQEX_wGDJ2nsgKgZBnUFf8srD9MCB6lipV4ewKAIqK9NbeUBmAKXIh2db7HL018XJ2dJ28ghMXjk66SfiVxb41XgwfR1qqS33SAst6mVXljBnRbS4c3H4oBT0vh-KpTTLs9MpnL-ia0VZeE_M0BJpXmOLjZYJVMftHISMWba82irQjfbYd9XcpngjlL0wxS-XFSTR8nssO1GuJObhtFjwjOFRl90v_zD7F32BkGTpnSxXvaVrQc0E36PvbK39bSaf4saiN_R-fABBV3pzQ |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Quantification+of+Serum+High+Mobility+Group+Box+1+by+Liquid+Chromatography%2FHigh-Resolution+Mass+Spectrometry%3A+Implications+for+Its+Role+in+Immunity%2C+Inflammation%2C+and+Cancer&rft.jtitle=Analytical+chemistry+%28Washington%29&rft.au=Weng%2C+Liwei&rft.au=Guo%2C+Lili&rft.au=Vachani%2C+Anil&rft.au=Mesaros%2C+Clementina&rft.date=2018-06-19&rft.issn=1520-6882&rft.eissn=1520-6882&rft.volume=90&rft.issue=12&rft.spage=7552&rft_id=info:doi/10.1021%2Facs.analchem.8b01175&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1520-6882&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1520-6882&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1520-6882&client=summon |